HDAC9 and myelodysplastic syndrome: In pre-clinical myelodysplastic syndrome (MDS) models, co-administration of an HDAC inhibitor with the demethylating agent azacitidine produced synergistic effects, illustrating the promise of combinatorial PTM modulation.